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Abstract 
Background: Patients with aortic stenosis (AS) may develop heart failure even in the absence of 
severe valve stenosis. Our aim was to assess the contribution of systemic arterial properties and 
the global left ventricular afterload to graded heart failure symptoms in AS. 
Methods: We retrospectively reviewed medical records of 157 consecutive subjects (mean age, 
71±10 years; 79 women and 78 men) hospitalized owing to moderate-to-severe degenerative AS. 
Exclusion criteria included more than mild aortic insufficiency or disease of another valve, atrial 
fibrillation, coronary artery disease, severe respiratory disease or anemia. Heart failure symptoms 
were graded by NYHA class at admission. Systemic arterial compliance (SAC) and valvulo-arterial 
impedance (Zva) were derived from routine echocardiography and blood pressure. 
Results: Sixty-one patients were asymptomatic, 49 presented mild (NYHA II) and 47 moder-
ate-to-severe (NYHA III–IV) heart failure symptoms. Mild symptoms were associated with lower 
SAC and transvalvular gradients, while more severe exercise intolerance coincided with older age, 
lower systolic blood pressure, smaller aortic valve area and depressed ejection fraction. By mul-
tiple ordinal logistic regression, the severity of heart failure symptoms was related to older age, 
depressed ejection fraction and lower SAC. Each decrease in SAC by 0.1 ml/m² per mmHg was 
associated with an increased adjusted odds ratio (OR) of a patient being in one higher category of 
heart failure symptoms graded as no symptoms, mild exercise intolerance and advanced exercise 
intolerance (OR: 1.16 [95% CI, 1.01–1.35], P=0.045).  
Conclusions: Depressed SAC may enhance exercise intolerance irrespective of stenosis severity 
or left ventricular systolic function in moderate-to-severe AS. This finding supports the im-
portance of non-valvular factors for symptomatic status in AS. 










According to the current clinical practice guide-
lines, in severe aortic stenosis (AS) interventional 
therapy is recommended in the presence of any 
symptoms related to AS [1]. It is well recognized that 
heart failure can appear even in subjects with moder-
ate AS and determination of their causal association 
with valve disease may be challenging. Impaired ex-
ercise tolerance is a result of an excessive left ventric-
ular (LV) afterload that is influenced not only by AS 
severity but also systemic arterial compliance (SAC) 
and peripheral vascular resistance, both of which 
augment LV systolic pressure additively to valve 
disease [2,3].  
 In 2005 the group of Pibarot [3] proposed a new 
index, valvulo-arterial impedance (Zva) that repre-
sents a total LV hemodynamic load opposing blood 
ejection into the aorta, and combines both valvular 
and arterial factors. Zva is equivalent to an estimated 
LV pressure divided by stroke volume indexed to 
body-surface area (stroke volume index, SVI) and, like 
SAC, may be easily derived from peripheral blood 
pressure and routine cardiac ultrasound examination. 
An increased Zva and depressed SAC were associated 
with a higher prevalence of LV diastolic and systolic 
dysfunction independently of other covariates in-
cluding aortic valve area (AVA) in 208 consecutive 
patients with moderate-to-severe AS, out of whom 
154 were symptomatic [3]. Additionally, a higher Zva 
was linked to a depressed stress-corrected LV mid-
wall shortening [4] and an elevated incidence of major 
cardiovascular events and aortic valve events in 
asymptomatic mild-to-moderate AS in the Simvas-
tatin and Ezetimibe in Aortic Stenosis (SEAS) study 
[5]. Furthermore, increased Zva was associated with a 
history of syncope in moderate-to-severe AS [6], an 
excessive mortality in severe AS with preserved EF 
(including 35% with paradoxically low flow [7]) and 
asymptomatic moderate-to-severe AS [8], and re-
duced event-free survival in asymptomatic moder-
ate-to-severe severe AS [9,10] upon multivariate ad-
justment.  
 Dulgheru et al. [11] have recently reported that 
increased Zva and older age were the only multivari-
ate determinants of reduced peak oxygen uptake in 62 
asymptomatic subjects with moderate-to-severe AS 
and preserved EF. To the best of our knowledge, as-
sociations between SAC or Zva and graded heart 
failure symptoms in AS have not been investigated so 
far. Thus, our aim was to estimate the contribution of 
altered systemic arterial properties and the global LV 
afterload to graded symptomatic status in degenera-
tive AS. 
Materials and Methods 
Patients 
We retrospectively reviewed medical records of 
157 consecutive patients (mean age, 71 ± 10 years; 79 
women and 78 men) hospitalized in a tertiary care 
center in 2008‒2013 owing to moderate-to-severe de-
generative AS defined as a calculated AVA ≤1.5 cm2 
(or AVA index ≤0.9 cm2/m2 body-surface area) or 
mean transvalvular pressure gradient ≥25 mmHg [1]. 
Exclusion criteria encompassed age below 50 years, 
more than mild coexisting aortic insufficiency, con-
comitant moderate or severe disease of another valve, 
atrial fibrillation, a history of myocardial infarction, 
coronary revascularization or a diameter stenosis of 
≥50% of at least one major epicardial artery segment 
on coronary angiography, significant peripheral ar-
tery disease or carotid stenosis, severe respiratory 
disease or anemia, body-mass index over 35 kg/m2, 
endocrinological disorders except for diabetes, severe 
renal insufficiency (estimated glomerular filtration 
rate below 30 ml/min per 1.73 m2), malignant or in-
flammatory disorders, and other relevant coexistent 
diseases or significant abnormalities in routine labor-
atory tests. The ethics committee of our university 
was notified about the planned analysis, similar to our 
previous report based on a retrospective data analysis 
[12]. 
Data collection 
Demographical and clinical patients’ character-
istics were recorded from discharge letters and hos-
pital records with heart failure symptoms graded by 
New York Heart Association (NYHA) functional 
classification at admission. Available measures of 
stenosis severity and LV structure and function were 
derived from transthoracic echocardiography and 
included peak and mean transvalvular pressure gra-
dient, calculated AVA, LV volumes, EF and LV mass. 
Transvalvular pressure gradients were obtained from 
continuous Doppler recordings by the modified Ber-
noulli formula. AVA was computed according to the 
standard continuity equation using the ratio of sub-
valvular to transvalvular time-velocity integrals. In 
agreement with the current recommendations EF was 
calculated by the biplane Simpson’s method [13]. LV 
mass index was estimated by the modified Devereux 
formula from M-mode measurements [14]. 
In addition, we computed an estimate of SAC as 
SVI divided by brachial pulse pressure measured at 
the time of echocardiographic examination [3,15]. Zva 
was calculated in a simplified manner because aortic 
diameter at the level of the sinotubular junction could 
not be obtained from a retrospective analysis of med-
ical records. This limitation precluded the computa-




tion of the so-called net mean aortic gradient that 
takes taking into account not only transvalvular gra-
dient at the vena contracta but also pressure recovery 
distal to the narrowed valve as proposed by Briand et 
al. [3] on the basis of the equation developed by 
Baumgartner et al. [16]. Thus, Zva was derived as the 
sum of systolic blood pressure and mean transvalvu-
lar pressure gradient divided by SVI, i.e. by a simpli-
fied approach which was nonetheless frequently used 
previously [7-11,17]. 
Statistical analysis 
Data are shown as mean and standard deviation, 
or numbers (n) and percentages. The patients were 
divided into 3 subgroups according to the degree of 
exercise intolerance i.e. asymptomatic subjects with 
no evidence of exertional dyspnea and/or fatigue or a 
syndrome of fluid retention in available medical rec-
ords, and those with a history of mild or advanced 
heart failure symptoms by NYHA functional class at 
admission. The accordance with a normal distribution 
was confirmed by Kolmogorov-Smirnov test and 
homogeneity of variances by Levene’s test. Intergroup 
differences were estimated by one-way analysis of 
variance (ANOVA) followed by the Tukey honest 
significant difference test for unequal n for continuous 
variables, and chi-squared test for categorical data. 
Bivariate associations were assessed by Pearson’s 
correlation coefficients (r). 
In order to identify independent determinants of 
the severity of symptoms, multiple ordinal logistic 
regression was performed, including only variables 
for which the P value in a univariate analysis was 
below 0.10. Odds ratios (OR) with 95% confidence 
intervals (CI) for the predictor variables have been 
shown for a patient being in one higher category of 
heart failure symptoms graded as no symptoms, mild 
exercise intolerance (NYHA II) and advanced exercise 
intolerance (NYHA III–IV). OR represents a multipli-
cative rise in the odds of a patient presenting worse 
categorized heart failure symptoms associated with 
each increment in the predictor variable by a given 
value (for continuous characteristics) or an increase in 
the odds in the patients exposed to a factor of interest 
(for dichotomous data). First, according to the ap-
proach proposed by Bender and Grouven [18], the 
goodness-of-fit of the binary logistic regression mod-
els was confirmed by the Hosmer-Lemeshow test for 
each dichotomized response, i.e., symptomatic vs. 
asymptomatic subjects and those with advanced 
symptoms vs. the remainder; then the proportional 
odds assumption was validated by means of a score 
test. A P value <0.05 was inferred significant. 
Results 
 Demographical and clinical characteristics of AS 
subjects by the presence and degree of heart failure 
symptoms are summarized in Table 1. Patients with 
mild symptoms tended to be more frequently men, 
whereas the presentation with advanced symptoms 
was related to an older age and weakly to lower mean 
blood pressure.  
Echocardiographic measures, systolic blood 
pressure, pulse pressure, Zva and SAC are shown in 
Table 2. The prevalence of mild symptoms associated 
with a significantly lower SAC and decreased trans-
valvular pressure gradients compared to asympto-
matic subjects. A more severe exercise intolerance 
coincided with a smaller AVA, lower systolic blood 
pressure and depressed EF (Table 2). 
SAC correlated to Zva (r = –0.69, P <0.001), SVI (r 
= 0.71, P <0.001), systolic blood pressure (r = –0.44, P 
<0.001), pulse pressure (r = –0.47, P <0.001), LV mass 
index (r = 0.37, P <0.001) and age (r = –0.24, P = 0.004).  




n = 61 
NYHA II 
n = 49 
NYHA III–IV 
n = 47 
 
P valuea 
Age, years 68 ± 11 71 ± 9 74 ± 9* 0. 005 
Female gender, n (%) 35 (57) 18 (37) 26 (55) 0.07 
Body-mass index, kg/m2 29.0 ± 4.6 29.9 ± 5.1 28.4 ± 4.9 0.31 
Hypertension, n (%) 47 (77) 44 (90) 38 (81) 0.21 
Diabetes mellitus, n (%) 20 (33) 17 (35) 17 (36) 0.93 
Chronic kidney disease, n (%) 12 (20) 11 (22) 12 (26) 0.77 
Mean blood pressure, mmHg 90 ± 11 92 ± 11 87 ± 12 0.12 
Drugs, n (%)     
 Diuretics 42 (69) 39 (80) 37 (79) 0.34 
 ACE inhibitors 26 (43) 25 (51) 22 (47) 0.89 
 Beta-blockers 33 (54) 24 (49) 20 (43) 0.49 
 Statins 36 (59) 30 (61) 29 (62) 0.95 
Data are presented as mean ± SD or n (%). 
aBy ANOVA or chi-squared test for continuous and categorical data, respectively. 
*P <0.05 vs. asymptomatic patients. 
Abbreviations: ACE: angiotensin-converting enzyme; NYHA: New York Heart Association functional class. 
 








n = 61 
NYHA II 
n = 49 
NYHA III–IV 
n = 47 
P value 
by ANOVA 
AVA, cm2 0.94 ± 0.34 1.01 ± 0.27 0.86 ± 0.29† 0.04 
Peak aortic gradient, mmHg 71 ± 31 57 ± 30* 68 ± 32 0.04 
Mean aortic gradient, mmHg 44 ± 21 34 ± 20* 41 ± 22 0.04 
Systolic blood pressure, mmHg 131 ± 15 137 ± 16 129 ± 17† 0.03 
Pulse pressure, mmHg 60 ± 14 67 ± 15 63 ± 16 0.07 
EF, % 57 ± 10 51 ± 14 49 ± 12* 0.01 
LV mass index, g/m2 147 ± 54 141 ± 45 166 ± 63 0.17 
SVI, ml/m2 37 ± 10 35 ± 10 36 ± 14 0.67 
Zva, mmHg per ml/m2 5.1 ± 1.7 5.2 ± 1.4 5.7 ± 2.3 0.36 
SAC, ml/m2 per mmHg 0.65 ± 0.23 0.54 ± 0.18* 0.57 ± 0.22 0.03 
Data are presented as mean ± SD. 
*P <0.05 vs. asymptomatic patients, †P <0.05 vs. NYHA-II patients by Tukey’s test. 
Abbreviations: AVA: aortic valve area; EF: ejection fraction; LV: left ventricular; NYHA: New York Heart Association functional class; SAC: systemic arterial compliance; 
SVI: stroke volume index; Zva: valvulo-arterial impedance. 
Table 3. Multiple ordinal logistic regression analysis of predictors of the severity of heart failure symptoms graded as no symptoms, mild 




 Odds ratio (OR) of a patient being in one higher symptomatic category 
Wald 
statistic 
Mean OR (95% CI) P value 
Age (per 10-year increment) 9.45 1.70 (1.21–2.39) 0.002 
Gender (men vs. women) 0.04 1.03 (0.75−1.42) 0.85 
AVA index (per 0.1-cm2 decrement) 1.66 1.14 (0.93–1.41) 0.19 
EF (per 10% decrement) 7.64 1.42 (1.11–1.81) 0.006 
SAC (per decrease of 0.1 ml/m² per mmHg) 4.11 1.16 (1.01−1.35) 0.045 
CI: confidence interval; other abbreviations as in Table 2. 
 
 
 Owing to the results of intergroup comparisons, 
age, gender, AVA, EF and SAC were included in the 
multiple ordinal logistic regression with the catego-
rized severity of heart failure symptoms as a de-
pendent variable. As mean transaortic pressure gra-
dient correlated closely to peak transaortic gradient (r 
= 0.97, P <0.001) and AVA index (r = −0.62, P <0.001), 
only the latter was entered into the regression. Addi-
tionally, because of the previously mentioned rela-
tions between SAC, systolic blood pressure and pulse 
pressure, blood pressure was not included in the re-
gression model. Multivariate analysis revealed the 
association of heart failure symptoms severity with an 
older age, depressed EF and decreased SAC (Table 3).  
Discussion 
 Our salient finding is that depressed systemic 
arterial compliance was associated with the severity 
of heart failure symptoms irrespective of AVA or EF 
in moderate-to-severe degenerative AS. That im-
paired systemic arterial properties were related to 
worse graded heart failure symptoms, supplements 
previous observations indicative of a limited predic-
tive value of classical indices of stenosis severity or LV 
function with regard to symptomatic status in AS. 
Predictors of symptomatic status in aortic 
stenosis 
 Over 10 years ago, Tongue et al. [19] identified 
impaired LV longitudinal shortening but not EF as an 
independent predictor of the presence of symptoms, 
mainly exertional dyspnea or angina, in addition to 
age and lower AVA index in moderate-to-severe AS. 
That study suggested the association of symptomatic 
status with LV longitudinal systolic function, gov-
erned by subendocardial fibers known to be more 
susceptible to microvascular ischemia due to an im-
balance between decreased myocardial perfusion and 
increased systolic wall stress in AS. This observation 
was later extended by Weidemann et al. [20] who 
found graded associations with the degree of myo-
cardial fibrosis – detected mainly at the subendocar-
dial layer – for higher NYHA functional class, lower 
systolic mitral ring displacement and depressed LV 
longitudinal strain rate but not LV radial strain rate, 
EF or AVA. In line with these findings, the selective 
impairment of LV longitudinal contraction was de-
scribed in patients with clinically asymptomatic se-
vere AS and an abnormal response to exercise [21]. 
With regard to diastolic dysfunction, Dalsgaard et al. 
[22] observed that symptomatic status in severe AS 
was independently related not to AVA but to invasive 
and noninvasive indices of increased LV filling pres-
sure. In keeping with this report, Dahl et al. [23] iden-
tified moderate or severe diastolic dysfunction as an 
independent determinant of the prevalence of symp-
toms in severe AS. 
  Importantly, the contribution of vascular factors 
to LV load was already suggested in 2003 by Anto-
nini-Canterin et al. [2] who reported that patients with 




coexisting hypertension and symptomatic AS pre-
sented with a similar degree of symptoms despite 
larger AVAs compared to normotensive subjects, 
probably because of an additional burden imposed on 
the left ventricle due to hypertension itself. In ac-
cordance with this early observation, Briand et al. [3] 
found a higher prevalence of symptoms, elevated 
systolic blood pressure, systemic vascular resistance 
and Zva, as well as an increased occurrence of LV 
systolic and diastolic dysfunction in severe AS and 
depressed SAC compared to their control counter-
parts with normal SAC despite similar indexed AVA. 
Furthermore, Ramamurthi et al. [24] observed an al-
most 2-fold higher prevalence of excessive vascular 
load in symptomatic vs. asymptomatic patients with 
moderate or severe AS. 
 However, the vast majority of the above cited 
cross-sectional studies aimed at the search for deter-
minants of symptomatic status in AS either did not 
differentiate between exertional dyspnea, angina and 
syncope pooling all these AS manifestations together 
[2,3,19,22-24] or limited their analysis to a history of 
syncope [6], while we have focused our attention on 
NYHA functional class. Importantly, Park et al. [25] 
described characteristic intracardiac hemodynamic 
profiles for each type of presenting symptoms (syn-
cope, dyspnea, and chest pain) in patients with severe 
AS with more advanced diastolic dysfunction associ-
ated with exertional dyspnea despite similar AVA 
and EF. It is noteworthy that, according to Dulgheru 
et al. [11], a negative association of Zva and peak ox-
ygen consumption was maintained in multiple re-
gression in 62 asymptomatic moderate-to-severe AS 
patients. Additionally, in that study [11] neither AVA 
nor EF was related to exercise capacity, whereas uni-
variate correlations between peak oxygen consump-
tion and tissue Doppler indices of systolic and dias-
tolic LV function lost significance upon multivariate 
adjustment. That the role of vascular factors may be 
predominant in this setting, was also suggested by 
Rajani et al. [26] who observed that only decreased 
SAC and closely interrelated higher pulse wave ve-
locity were univariate correlates of depressed exercise 
time in 101 patients with asymptomatic moder-
ate-to-severe AS. Because they have not observed 
such a relationship for Zva [26], their results are in 
part compatible with our findings. Of note, Roşca et 
al. [27] observed independent associations of an index 
of aortic rigidity but not Zva with LV longitudinal 
deformation, E/E’ ratio and B-type natriuretic peptide 
concentrations in 48 consecutive patients with severe 
AS. Finally, total arterial compliance, depressed in 
severe AS, not only did not increase with exercise in 
contrast to control subjects, but this impairment was a 
negative determinant of the exercise-induced increase 
in stroke flow [28], which further strengthens the po-
tential importance of altered systemic arterial proper-
ties for impaired exercise tolerance in AS. 
Clinical implications 
 Our findings add to accumulating evidence 
supporting the clinical relevance of excessive arterial 
stiffness as demonstrated by Albu et al. [29] who ob-
served that increased pulse wave velocity, an index of 
lower SAC, was the only significant predictor of LV 
diastolic dysfunction in 96 postmenopausal women 
without overt cardiovascular disease. 
 Taking into consideration the contribution of 
vascular components to exercise intolerance in AS, it 
may be hypothesized that interventions aimed at im-
proving elastic properties of large arteries can delay 
symptom onset in AS. In a randomized place-
bo-controlled study Dalsgaard et al. [30] have recently 
shown that angiotensin-converting enzyme (ACE) 
inhibition with trandolapril – associated with a rise in 
SAC at day 3 – resulted in a lower LV end-systolic 
volume and decreased levels of N-terminal 
pro-B-type natriuretic peptide after a median fol-
low-up of 7 weeks compared to placebo in 44 patients 
with severe AS, out of whom 32 were symptomatic. 
As B-type natriuretic peptides increase with the 
NYHA class [31] and predict the development of 
symptoms in AS [32], these findings appear consistent 
with the notion of hemodynamic benefits of ACE an-
tagonists in AS. On the other hand, no effect of tran-
dolapril on exercise capacity was found over the fol-
low-up [30], which is somewhat contradictory to the 
report by Chockalingam et al. [33] who observed 
symptomatic improvement and better exercise toler-
ance after 1–3 months in 52 patients with severe 
symptomatic AS randomized to enalapril, although 
these effects were limited to those with a good toler-
ance of the drug. In addition, in a drug withdrawal 
study of 20 asymptomatic hypertensive subjects with 
moderate-to-severe AS Jiménez-Candil et al. [34] re-
ported that stroke volume at peak exercise was higher 
when patients were taking ACE inhibitors, and cor-
related inversely to changes in systemic vascular re-
sistance, nevertheless, exercise duration was unaf-
fected by the medication.  
 Hence, further studies are warranted to deter-
mine if beneficial hemodynamic effect of ACE an-
tagonists in AS observed in some clinical settings may 
be linked to their influence on arterial compliance or 
peripheral vascular resistance, as well as whether 
ACE inhibitors could favorably affect symptomatic 
status in patients unsuitable for or awaiting surgery or 
transcatheter aortic valve implantation. Importantly, 
as the results of these interventions are frequently 
suboptimal, the ACE inhibition-induced rise in SAC 




could hypothetically be useful in postoperative man-
agement, e.g. in paradoxical low-flow, low-gradient 
severe AS associated with depressed SAC, pro-
nounced LV myocardial fibrosis and a poorer clinical 
outcome after surgery than high-gradient AS 
[7,17,23,35,36].  
Strengths and limitations of the study 
 The strength of our study was the ability to 
demonstrate an association of the severity of heart 
failure symptoms in AS with altered systemic arterial 
properties despite the use of only a retrospective 
analysis of routine medical records. Moreover, the 
study subjects represented a real-life population of 
consecutive patients with AS and we made every ef-
fort to limit the contribution of coexistent diseases to 
symptomatic status applying a wide set of exclusion 
criteria including significant coronary artery disease. 
 However, several limitations of the present 
study need to be acknowledged. First, heart failure 
symptoms were graded according to NYHA classifi-
cation at admission although a better measure of ex-
ercise capacity would be advisable. Furthermore, as-
sessment of symptoms in elderly AS patients is chal-
lenging because of a decreased physical activity of 
these subjects. Nevertheless, due to a retrospective 
study design with hospital discharge charts as source 
documentation, we could only include NYHA class, 
not a rarely used exercise tolerance test, in the final 
dataset. For the same reason, EF was the only index of 
LV systolic function. On the other hand, the NYHA 
class and EF still remain the basis of clinical deci-
sion-making in AS. Second, as mentioned previously 
in the Data collection subsection, Zva was derived by 
a simplified method [3,16] from the parameters 
available from our medical records. Third, although 
Doppler echocardiographic evaluation of AS should 
be performed when blood pressure control is optimal 
[37], this condition could not be unequivocally con-
firmed in all patients hospitalized during previous 
years. Finally, the lack of data on B-type natriuretic 
peptide – a marker of hemodynamic burden and ad-
verse outcome [38] – as well as on the exact time of 
symptom onset constrains conclusions based on our 
cross-sectional analysis of associations between SAC 
and graded heart failure symptoms. 
Conclusions 
 In summary, depressed systemic arterial com-
pliance might enhance exercise intolerance irrespec-
tive of stenosis severity or left ventricular systolic 
function in moderate-to-severe degenerative AS, 
which supports the relevance of non-valvular factors 
for symptomatic status in AS. Whether medical ther-
apy aimed at improving elastic properties of large 
arteries can relieve symptoms, especially in patients 
with moderate valve disease, or facilitate postopera-
tive clinical improvement in AS, remains to be stud-
ied. 
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